Mergers and acquisitions – Page 14
-
Business
Bruker winds down underperforming instrument lines
Stand-alone gas chromatographs and certain mass spectrometry products to be sold off
-
Business
Reckitt Benckiser to spin out US pharma arm
Declining heroin addiction treatment sales prompt divestment as company focuses on over-the-counter and consumer products
-
BusinessPharma firms rush to escape US tax shackles
AbbVie–Shire and Mylan–Abbott mergers both allow US firms to escape to lower-tax European countries
-
Business
Albemarle buys into lithium with Rockwood merger
$6.2 billion deal capitalises on battery market growth
-
Business
ADM to buy food ingredients specialist Wild Flavors
€2.3bn deal gets ADM into rapidly-growing area of naturally-sourced flavourings
-
Business
Ineos takes full control of Styrolution
€1.1bn deal sees BASF complete its planned exit from styrenics joint venture
-
Business
Genentech to buy breast cancer specialist Seragon
$1.7bn deal for hormone receptor-destroying drug pipeline
-
PodcastChemistry World podcast - July 2014
We speak to artist Briony Marshall and art detective Warren Warren about the more artistic sides of chemistry
-
Business
PPG to buy Mexican paints firm Comex
$2.3bn deal expands US firm’s footprint in Central America
-
Business
Affymax folds after drug withdrawal
Unexplained allergic reactions to anaemia drug prompt firm to dissolve
-
Business
Shire fends off AbbVie takeover bid
Board says deal undervalues the company and its growth potential
-
Business
Medtronic to buy Covidien for $43bn
Tax inversion deal continues consolidation theme among medical device makers
-
BusinessPharma vies to unleash immune system power on cancer
Immuno-oncological drugs look set to earn billions and significantly lengthen patients’ lives
-
Business
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition
Early-stage drugs complement Merck’s own developmental portfolio
-
PodcastChemistry World podcast - June 2014
We speak to Tom Brown, the 2014 Chemistry World Entrepreneur of the Year, and find out why cells spend so much time doing nothing
-
OpinionMessy megamergers
Big company buyouts are more about immediate gains and rarely consider the impact on research, says Derek Lowe
-
Business
Time called on Pfizer–AstraZeneca deal
Pfizer could make a fresh approach after six months under City takeover rules
-
Business
Mitsui continues reinvention efforts with two deals
Japanese firm drops organic acids in favour of lens materials
-
Business
Novartis enhances its focus with eyecare deal
Swiss firm buys rights to wet AMD drug from Ophthotech for up to $1bn